Clinical Trial Update: A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial in Asia assessing second-line nivolumab monotherapy for non-small cell lung cancer has completed and posted results in July 2024. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lung Cancer, Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-07-18